Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases
147
Zitationen
28
Autoren
2021
Jahr
Abstract
BACKGROUND: Clinical interpretation of genetic variants in the context of the patient's phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases. Artificial intelligence (AI) holds promise to greatly simplify and speed genome interpretation by integrating predictive methods with the growing knowledge of genetic disease. Here we assess the diagnostic performance of Fabric GEM, a new, AI-based, clinical decision support tool for expediting genome interpretation. METHODS: We benchmarked GEM in a retrospective cohort of 119 probands, mostly NICU infants, diagnosed with rare genetic diseases, who received whole-genome or whole-exome sequencing (WGS, WES). We replicated our analyses in a separate cohort of 60 cases collected from five academic medical centers. For comparison, we also analyzed these cases with current state-of-the-art variant prioritization tools. Included in the comparisons were trio, duo, and singleton cases. Variants underpinning diagnoses spanned diverse modes of inheritance and types, including structural variants (SVs). Patient phenotypes were extracted from clinical notes by two means: manually and using an automated clinical natural language processing (CNLP) tool. Finally, 14 previously unsolved cases were reanalyzed. RESULTS: GEM ranked over 90% of the causal genes among the top or second candidate and prioritized for review a median of 3 candidate genes per case, using either manually curated or CNLP-derived phenotype descriptions. Ranking of trios and duos was unchanged when analyzed as singletons. In 17 of 20 cases with diagnostic SVs, GEM identified the causal SVs as the top candidate and in 19/20 within the top five, irrespective of whether SV calls were provided or inferred ab initio by GEM using its own internal SV detection algorithm. GEM showed similar performance in absence of parental genotypes. Analysis of 14 previously unsolved cases resulted in a novel finding for one case, candidates ultimately not advanced upon manual review for 3 cases, and no new findings for 10 cases. CONCLUSIONS: GEM enabled diagnostic interpretation inclusive of all variant types through automated nomination of a very short list of candidate genes and disorders for final review and reporting. In combination with deep phenotyping by CNLP, GEM enables substantial automation of genetic disease diagnosis, potentially decreasing cost and expediting case review.
Ähnliche Arbeiten
Trimmomatic: a flexible trimmer for Illumina sequence data
2014 · 68.541 Zit.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
2015 · 31.523 Zit.
BEDTools: a flexible suite of utilities for comparing genomic features
2010 · 30.028 Zit.
HTSeq—a Python framework to work with high-throughput sequencing data
2014 · 22.482 Zit.
A global reference for human genetic variation
2015 · 19.702 Zit.
Autoren
- Francisco M. De La Vega
- Shimul Chowdhury
- Barry Moore
- Erwin Frise
- Jeanette McCarthy
- Edgar J. Hernández
- Terence C. Wong
- Kiely N. James
- Lucia Guidugli
- Pankaj B. Agrawal
- Casie A. Genetti
- Catherine A. Brownstein
- Alan H. Beggs
- Britt-Sabina Löscher
- André Franke
- Braden Boone
- Shawn Levy
- Katrin Õunap
- Sander Pajusalu
- Matt Huentelman
- Keri Ramsey
- Marcus Naymik
- Vinodh Narayanan
- Narayanan Veeraraghavan
- Paul R. Billings
- Martin G. Reese
- Mark Yandell
- Stephen F. Kingsmore
Institutionen
- Tempus Labs (United States)(US)
- ID Genomics (United States)(US)
- Stanford University(US)
- Children’s Institute(US)
- University of Utah(US)
- Boston Children's Hospital(US)
- Harvard University(US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center(US)
- Christian-Albrechts-Universität zu Kiel(DE)
- University Hospital Schleswig-Holstein(DE)
- University of Lübeck(DE)
- HudsonAlpha Institute for Biotechnology(US)
- Tartu University Hospital(EE)
- University of Tartu(EE)
- Translational Genomics Research Institute(US)
- Star Center(US)